IGM Biosciences (IGMS) Competitors $1.27 0.00 (0.00%) As of 08/14/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock IGMS vs. DSGN, RNAC, DRUG, NGNE, HUMA, PBYI, ACB, GLUE, FHTX, and AVIRShould you be buying IGM Biosciences stock or one of its competitors? The main competitors of IGM Biosciences include Design Therapeutics (DSGN), Cartesian Therapeutics (RNAC), Bright Minds Biosciences (DRUG), Neurogene (NGNE), Humacyte (HUMA), Puma Biotechnology (PBYI), Aurora Cannabis (ACB), Monte Rosa Therapeutics (GLUE), Foghorn Therapeutics (FHTX), and Atea Pharmaceuticals (AVIR). These companies are all part of the "pharmaceutical products" industry. IGM Biosciences vs. Its Competitors Design Therapeutics Cartesian Therapeutics Bright Minds Biosciences Neurogene Humacyte Puma Biotechnology Aurora Cannabis Monte Rosa Therapeutics Foghorn Therapeutics Atea Pharmaceuticals IGM Biosciences (NASDAQ:IGMS) and Design Therapeutics (NASDAQ:DSGN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, media sentiment and analyst recommendations. Does the media prefer IGMS or DSGN? In the previous week, Design Therapeutics had 2 more articles in the media than IGM Biosciences. MarketBeat recorded 2 mentions for Design Therapeutics and 0 mentions for IGM Biosciences. IGM Biosciences' average media sentiment score of 0.00 beat Design Therapeutics' score of -0.32 indicating that IGM Biosciences is being referred to more favorably in the media. Company Overall Sentiment IGM Biosciences Neutral Design Therapeutics Neutral Which has higher valuation and earnings, IGMS or DSGN? Design Therapeutics has lower revenue, but higher earnings than IGM Biosciences. Design Therapeutics is trading at a lower price-to-earnings ratio than IGM Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIGM Biosciences$145.05M0.53-$195.79M-$0.90-1.41Design TherapeuticsN/AN/A-$49.59M-$1.12-4.70 Which has more volatility and risk, IGMS or DSGN? IGM Biosciences has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500. Comparatively, Design Therapeutics has a beta of 1.58, indicating that its stock price is 58% more volatile than the S&P 500. Do insiders & institutionals believe in IGMS or DSGN? 42.8% of IGM Biosciences shares are owned by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are owned by institutional investors. 57.0% of IGM Biosciences shares are owned by insiders. Comparatively, 23.5% of Design Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is IGMS or DSGN more profitable? Design Therapeutics has a net margin of 0.00% compared to IGM Biosciences' net margin of -36.81%. Design Therapeutics' return on equity of -27.15% beat IGM Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets IGM Biosciences-36.81% -93.35% -24.15% Design Therapeutics N/A -27.15%-26.07% Do analysts rate IGMS or DSGN? IGM Biosciences presently has a consensus price target of $5.50, indicating a potential upside of 333.07%. Given IGM Biosciences' stronger consensus rating and higher possible upside, research analysts plainly believe IGM Biosciences is more favorable than Design Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IGM Biosciences 1 Sell rating(s) 9 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.90Design Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryIGM Biosciences beats Design Therapeutics on 8 of the 14 factors compared between the two stocks. Get IGM Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for IGMS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IGMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IGMS vs. The Competition Export to ExcelMetricIGM BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$76.57M$3.11B$5.81B$9.77BDividend YieldN/A2.23%4.40%4.06%P/E Ratio-1.4121.0031.3026.05Price / Sales0.53209.34389.4489.48Price / CashN/A44.5038.0259.36Price / Book0.768.129.536.60Net Income-$195.79M-$54.72M$3.26B$265.65M7 Day PerformanceN/A2.62%2.13%1.99%1 Month Performance-0.78%3.25%3.21%0.45%1 Year Performance-87.85%10.82%30.18%18.87% IGM Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IGMSIGM Biosciences4.2939 of 5 stars$1.27flat$5.50+333.1%N/A$76.57M$145.05M-1.41190DSGNDesign Therapeutics0.1637 of 5 stars$5.40+1.3%N/A+7.6%$303.53MN/A-4.8240RNACCartesian Therapeutics2.6051 of 5 stars$11.28-0.4%$40.00+254.6%-18.3%$294.60M$38.91M-0.2164Positive NewsGap UpDRUGBright Minds Biosciences2.6741 of 5 stars$45.55+8.9%$83.25+82.8%+4,252.5%$294.58MN/A-48.98N/ATrending NewsAnalyst ForecastAnalyst RevisionNGNENeurogene1.7251 of 5 stars$20.45-0.3%$46.17+125.8%-42.8%$292.72M$930K-4.7490HUMAHumacyte2.3478 of 5 stars$1.80-4.3%$10.64+491.3%-77.5%$291.62M$1.57M-4.00150Insider TradePBYIPuma Biotechnology4.0865 of 5 stars$5.01-12.6%$7.00+39.7%+106.7%$288.63M$238.06M5.11200High Trading VolumeACBAurora Cannabis0.8015 of 5 stars$5.12+0.8%N/A-23.3%$286.79M$246.72M-26.951,130GLUEMonte Rosa Therapeutics2.6082 of 5 stars$4.56-0.4%$15.33+236.3%-23.9%$282.86M$75.62M12.6790FHTXFoghorn Therapeutics2.2789 of 5 stars$5.10+2.4%$12.00+135.3%-30.6%$281.52M$22.60M-4.29120Positive NewsAVIRAtea Pharmaceuticals1.7274 of 5 stars$3.53+0.9%$6.00+70.0%-6.2%$277.75MN/A-2.1970 Related Companies and Tools Related Companies DSGN Alternatives RNAC Alternatives DRUG Alternatives NGNE Alternatives HUMA Alternatives PBYI Alternatives ACB Alternatives GLUE Alternatives FHTX Alternatives AVIR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IGMS) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersNations are at war over what’s in this boxA resource known as Element 29 is quickly becoming one of the most sought-after materials on the planet. Goldm...Behind the Markets | SponsoredCould This Be the End of Retirement Worries?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IGM Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IGM Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access